Evidence map›Paper›PMID 23166561›Full record

ArticleDrug discovery today. Technologies2012

NMR in the Analysis of Functional Chemokine Interactions and Drug Discovery.

Joshua J Ziarek, Brian F Volkman

Open access · greenAbstract read
In one paragraph

Article in Drug discovery today. Technologies, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Joshua J ZiarekDepartment of Biochemistry, Medical College of Wisconsin, 8701 West Watertown Plank Road, Milwaukee, Wisconsin 53226 USA.
Brian F Volkman
Medical College of Wisconsin · US

Funding

Structural Basis for Chemokine FunctionR01AI058072 · NIAID · MEDICAL COLLEGE OF WISCONSIN · PI VOLKMAN, BRIAN F · 2004 to 2019
$4.1M
Sulfotyrosine-guided discovery of small molecule chemokine inhibitorsR01GM097381 · NIGMS · MEDICAL COLLEGE OF WISCONSIN · PI VOLKMAN, BRIAN F · 2011 to 2021
$2.9M
Structural Basis for Chemokine FunctionR37AI058072 · NIAID · MEDICAL COLLEGE OF WISCONSIN · PI Brian F Volkman · 2020 to 2026
$2.8M
Conformational duality in the human chemokine Ltn/XCL1R01AI063325 · NIAID · MEDICAL COLLEGE OF WISCONSIN · PI VOLKMAN, BRIAN F · 2005 to 2009
$1.4M
500 MHz NMR Spectrometer at the Medical College of WisconsinS10RR024665 · NCRR · MEDICAL COLLEGE OF WISCONSIN · PI VOLKMAN, BRIAN F · 2009 to 2009
$500k
Conformational duality in the human chemokine Ltn/XCL1R56AI063325 · NIAID · MEDICAL COLLEGE OF WISCONSIN · PI VOLKMAN, BRIAN F · 2011 to 2011
$352k
NCRR NIH HHS S10 RR024665NIAID NIH HHS R01 AI058072NIAID NIH HHS R01 AI063325NIAID NIH HHS R37 AI058072NIAID NIH HHS R56 AI063325NIGMS NIH HHS R01 GM097381
6 · The paper itself

Abstract

The involvement of chemokines and chemokine receptors in a great variety of pathological indications underscores their utility as therapeutic targets. In general, chemokine-mediated migration and signaling requires three distinct interactions: self-association, glycosaminoglycan (GAG) binding, and activation of G protein-coupled receptors (GPCRs). Solution-state nuclear magnetic resonance (NMR) spectroscopy has long been used to determine the apo structure of chemokines and monitor complex formation; however, it has never contributed directly to drug discovery efforts that are traditionally focused on the previously inaccessible chemokine receptors. Our lab recently demonstrated that NMR structures can be successfully utilized to direct drug discovery against chemokines. The ease of collecting chemokine structural data coupled with the increased efficiency of structure-based drug discovery campaigns makes chemokine-directed therapies particularly attractive. In addition, recent advances in sample preparation, spectrometer hardware, and pulse program development are allowing researchers to examine interactions with previously inaccessible partners - including full-length chemokine receptors. These developments will facilitate exploration of novel ways to modulate chemokine activity using structure-guided drug discovery.

Identifiers

PMID23166561
PMCPMC3499625
OpenAlexW2035748029

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.